Tissue Regenix Group plc (LON:TRX) Insider Brian Phillips Purchases 6,773 Shares

Tissue Regenix Group plc (LON:TRXGet Free Report) insider Brian Phillips acquired 6,773 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was purchased at an average cost of GBX 54 ($0.68) per share, with a total value of £3,657.42 ($4,576.92).

Tissue Regenix Group Stock Performance

LON:TRX opened at GBX 54 ($0.68) on Friday. The company has a debt-to-equity ratio of 31.84, a current ratio of 3.77 and a quick ratio of 2.36. The firm has a 50-day moving average of GBX 52.97 and a two-hundred day moving average of GBX 37.53. The stock has a market cap of £38.11 million, a P/E ratio of -2,700.00 and a beta of 1.53. Tissue Regenix Group plc has a 1-year low of GBX 46.80 ($0.59) and a 1-year high of GBX 71 ($0.89).

Tissue Regenix Group Company Profile

(Get Free Report)

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. It operates in three segments: dCELL, BioRinse, and GBM-V. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth.

See Also

Receive News & Ratings for Tissue Regenix Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group and related companies with MarketBeat.com's FREE daily email newsletter.